Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Alfica Sehgal(Alnylam Pharmaceuticals (United States)), Daniel G. Anderson(Massachusetts Institute of Technology), Emmanouil D. Karagiannis(McGovern Institute for Brain Research), Christopher Zurenko(Alnylam Pharmaceuticals (United States)), Angela I. Park(Massachusetts Institute of Technology), Kevin T. Love(Massachusetts Institute of Technology), Chang G. Peng(Alnylam Pharmaceuticals (United States)), Róbert Langer(Massachusetts Institute of Technology), Anna Borodovsky(Brigham and Women's Hospital), Abigail K. R. Lytton‐Jean(Massachusetts Institute of Technology), Muthusamy Jayaraman(Forma Therapeutics (United States)), William Querbes(Alnylam Pharmaceuticals (United States)), Matthias Nahrendorf(Massachusetts General Hospital), Hyuckjin Lee, Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Jessica Donahoe(Center for Systems Biology), Yi Chen(Guangzhou University of Chinese Medicine), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Jessica Truelove(Massachusetts General Hospital)
DSpace@MIT (Massachusetts Institute of Technology)
June 1, 2012
Cited by 0
Related Papers
Transdermal drug delivery
|Nature Biotechnology|2008|3.4k
Physical and mechanical properties of PLA, and their functions in widespread applications — A comprehensive review
|Advanced Drug Delivery Reviews|2016|3.2k
Knocking down barriers: advances in siRNA delivery
|Nature Reviews Drug Discovery|2009|3.1k
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k